Abstract
Introduction We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) comparing blonanserin with other antipsychotics (amisulpride, aripiprazole, haloperidol, paliperidone, and risperidone). Methods Weighted mean difference (WMD), risk ratio, and number needed to harm (NNH) with 95% confidence intervals (95% CIs) were calculated using random-effects model. Results Ten RCTs (n = 1521) were included in this study. Blonanserin was superior to aripiprazole in improvement of Positive and Negative Syndrome Scale total scores (WMD = -10.62, 95% CI = -17.67 to -3.560, p = 0.003). Blonanserin was associated with a higher incidence of all-cause discontinuation (RR = 1.373, 95% CI = 1.088-1.734, p = 0.008, NNH = 11), akathisia, extrapyramidal disorder, and agitation/excitement and a lower risk of hyperprolactinemia compared with risperidone + paliperidone. Discussion The current meta-analytic study did not update the comparison of blonanserin vs. haloperidol because there were no new RCTs. Our results suggest that the efficacy of blonanserin for schizophrenia is comparable with that of other antipsychotics, and blonanserin seems to be well tolerated.
| Original language | English |
|---|---|
| Pages (from-to) | 52-62 |
| Number of pages | 11 |
| Journal | Pharmacopsychiatry |
| Volume | 52 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 07-03-2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Psychiatry and Mental health
- Pharmacology (medical)
Cite this
}
Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia : An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials. / Kishi, Taro; Matsui, Yuki; Matsuda, Yuki; Katsuki, Asuka; Hori, Hikaru; Yanagimoto, Hiroko; Sanada, Kenji; Morita, Kiichiro; Yoshimura, Reiji; Shoji, Yoshihisa; Hagi, Katsuhiko; Iwata, Nakao.
In: Pharmacopsychiatry, Vol. 52, No. 2, 07.03.2019, p. 52-62.Research output: Contribution to journal › Article
TY - JOUR
T1 - Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia
T2 - An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials
AU - Kishi, Taro
AU - Matsui, Yuki
AU - Matsuda, Yuki
AU - Katsuki, Asuka
AU - Hori, Hikaru
AU - Yanagimoto, Hiroko
AU - Sanada, Kenji
AU - Morita, Kiichiro
AU - Yoshimura, Reiji
AU - Shoji, Yoshihisa
AU - Hagi, Katsuhiko
AU - Iwata, Nakao
PY - 2019/3/7
Y1 - 2019/3/7
N2 - Introduction We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) comparing blonanserin with other antipsychotics (amisulpride, aripiprazole, haloperidol, paliperidone, and risperidone). Methods Weighted mean difference (WMD), risk ratio, and number needed to harm (NNH) with 95% confidence intervals (95% CIs) were calculated using random-effects model. Results Ten RCTs (n = 1521) were included in this study. Blonanserin was superior to aripiprazole in improvement of Positive and Negative Syndrome Scale total scores (WMD = -10.62, 95% CI = -17.67 to -3.560, p = 0.003). Blonanserin was associated with a higher incidence of all-cause discontinuation (RR = 1.373, 95% CI = 1.088-1.734, p = 0.008, NNH = 11), akathisia, extrapyramidal disorder, and agitation/excitement and a lower risk of hyperprolactinemia compared with risperidone + paliperidone. Discussion The current meta-analytic study did not update the comparison of blonanserin vs. haloperidol because there were no new RCTs. Our results suggest that the efficacy of blonanserin for schizophrenia is comparable with that of other antipsychotics, and blonanserin seems to be well tolerated.
AB - Introduction We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) comparing blonanserin with other antipsychotics (amisulpride, aripiprazole, haloperidol, paliperidone, and risperidone). Methods Weighted mean difference (WMD), risk ratio, and number needed to harm (NNH) with 95% confidence intervals (95% CIs) were calculated using random-effects model. Results Ten RCTs (n = 1521) were included in this study. Blonanserin was superior to aripiprazole in improvement of Positive and Negative Syndrome Scale total scores (WMD = -10.62, 95% CI = -17.67 to -3.560, p = 0.003). Blonanserin was associated with a higher incidence of all-cause discontinuation (RR = 1.373, 95% CI = 1.088-1.734, p = 0.008, NNH = 11), akathisia, extrapyramidal disorder, and agitation/excitement and a lower risk of hyperprolactinemia compared with risperidone + paliperidone. Discussion The current meta-analytic study did not update the comparison of blonanserin vs. haloperidol because there were no new RCTs. Our results suggest that the efficacy of blonanserin for schizophrenia is comparable with that of other antipsychotics, and blonanserin seems to be well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=85043348163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043348163&partnerID=8YFLogxK
U2 - 10.1055/a-0574-0088
DO - 10.1055/a-0574-0088
M3 - Article
C2 - 29514360
AN - SCOPUS:85043348163
VL - 52
SP - 52
EP - 62
JO - Pharmacopsychiatry
JF - Pharmacopsychiatry
SN - 0176-3679
IS - 2
ER -